2 Phase III clinical studies treating acursion synodi, oral anti-inflammatory drug Olumiant (baricitinib), reach the main endpoint
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
acursion (AD) is a serious chronic inflammatory skin disease characterized by severe itching, noticeable eczema-like changes and dry skinrecently, U.SPharmaceutical(http://giant Eli Lilly and partner Incyte announced that the assessment of oral anti-inflammatory drug Olumiant (baricitinib) single-drug treatment of moderate to severe adhesion dermatitis (AD) adult patients 2 Phase III clinical studies (BREEZE-AD1, BREEZE-AD2) reached the main enda significantly higher percentage of patients in the Olumiant treatment group who achieved an AD IGA score of clear or almost clear (IGA 0,1) at the 16th week of treatment than in the placebo groupThe two studies are part of five placebo-controlled research projects that support the global registration of olumiant AD new indicationsduring the 16-week placebo control period of the two studies, the adverse and severe adverse events in the Olumiant treatment group were similar to those in the placebo group, with the most common adverse events occurring in treatment being nasopharyngitis and headachesNo venous thrombosis events (VTES), major adverse cardiovascular events (MACE), or reports of deathLilly plans to release full data from the two studies at the(http://of the future MedicalConference, and the other Phase III studies are expected to receive top-line data later this yearLilly and Incyte reached an exclusive partnership in 2009 to develop Orumiant and some subsequent compounds
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
